摘要
目的 分析苦黄注射液联合甘草酸二胺注射液对急性黄疸型病毒性肝炎患者的治疗疗效及其影响因素。方法 以随机数字表法将2022年7月至2023年7月我院收治的急性黄疸型病毒性肝炎患者80例均分为参照、研究组,均予以甘草酸二胺注射液治疗,研究组联合苦黄注射液治疗,并就临床疗效、不良反应、症状评分及肝功能进行观察对比。并进行了危险因素分析,探讨了影响疗效的独立危险因素。结果 (1)治疗总有效率研究组(97.50%)高于参照组(85.00%),对比有统计学意义(P<0.05)。(2)不良反应研究组发生率(7.50%)略低于参照组(12.50%),但对比无统计学意义(P>0.05)。(3)临床症状表现研究组总评分(4.60±2.12分)低于参照组(8.49±3.28分),对比有统计学意义(P<0.05)。(4)肝功能TBIL、DBIL、ALT、AST及γ-GT水平研究组(18.13±4.21μmol/L、18.34±4.14μmol/L、152.71±16.48U/L、140.68±12.51U/L、110.91±42.57U/L)低于参照组(24.62±4.23μmol/L、24.28±4.65μmol/L、171.84±20.59U/L、161.44±17.07U/L、134.62±51.04U/L),对比均有统计学意义(P<0.05);ALB水平(40.32±2.84g/L)与参照组(39.95±2.86g/L),对比无统计学意义(P>0.05)。危险因素分析显示,年龄>35(OR:5.488,95%CI:1.432-21.027,P=0.013)、病程>1年(OR:3.682,95%CI:1.168-11.611,P=0.026)、治疗前ALT>540U/L(OR:4.199,95%CI:1.369-12.879,P=0.012)和治疗方案(OR:4.123,95%CI:1.273-13.348,P=0.018)是影响患者疗效的独立危险因素。结论 苦黄注射液联合甘草酸二胺注射液治疗急性黄疸型病毒性肝炎可助患者改善肝功能,并加快症状表现消失速度,值得被进一步推广运用。
Objective To observe the efficacy of bitter yellow injection combined with glycyrrhizic acid diamine injection in the treatment of acute jaundice viral hepatitis.Methods A total of 80 patients with acute jaundice viral hepatitis admitted to our hospital from July 2022 to July 2023 were divided into reference and research groups,and all were treated with glycyrrhizinatediamine injection,and the study group was combined with bitter yellow injection,and the clinical efficacy,adverse reactions,symptom scores and liver function were observed and compared.conducted a risk factor analysis to investigate the independent risk factors affecting efficacy.Results (1)The total effective rate of treatment(97.50%)was higher than that in the control group(85.00%),and the comparison was statistically significant(P<0.05).(2)The incidence of adverse reactions in the study group(7.50%)was slightly lower than that in the control group(12.50%),but the comparison was not statistically significant(P>0.05).(3)The total score of the clinical symptom performance study group(4.60±2.12 points)was lower than that of the reference group(8.49±3.28 points),and the comparison was statistically significant(P<0.05).(4)The liver function TBIL,DBIL,ALT,AST andγ-GT levels(18.13±4.21μmol/L,18.34±4.14μmol/L,152.71±16.48U/L,140.68±12.51U/L,110.91±42.57U/L)were lower than those in the reference group(24.62±4.23μmol/L,24.28±4.65μmol/L,171.84±).20.59U/L,161.44±17.07U/L,134.62±51.04U/L),all of which were statistically significant(P<0.05);The ALB level(40.32±2.84 g/L)was not significantly compared with the reference group(39.95±2.86 g/L)(P>0.05).Risk factor analysis revealed that age>35(OR:5.488,95%CI:1.432-21.027,P=0.013),disease duration>1 year(OR:3.682,95%CI:1.168-11.611,P=0.026),pre-treatment ALT>540U/L(OR:4.199,95%CI:1.369-12.879,P=0.012),and treatment regimen(OR:4.123,95%CI:1.273-13.348,P=0.018)were independent risk factors affecting efficacy.Conclusion The treatment of acute jaundice viral hepatitis with bitter yellow injection combined with glycyrrhizate diamine injection can help patients improve liver function and accelerate the disappearance of symptoms,which is worthy of further promotion.
作者
贺强兴
赵崇
蔡正阳
HE Qiang-xing;ZHAO Chong;CAI Zheng-yang(Department of Respiratory Medicine,The Sixth People's Hospital of Nanyang City,Nanyang 473000 Henan Provinc,China)
出处
《罕少疾病杂志》
2025年第1期96-98,共3页
Journal of Rare and Uncommon Diseases
基金
2019河南省医学科技攻关计划(联合共建)项目(LHGJ20190686)。
关键词
苦黄注射液
甘草酸二胺注射液
急性黄疸型病毒性肝炎
症状评分
肝功能
Bitter Yellow Injection
Glycyrrhizinatediamine Injection
Acute Jaundice Viral Hepatitis
Symptom Scores
Liver Function
